Jardiance (Empagliflozin) Efficacy in South Asian Patients: Documented Gaps and Clinical Considerations

Why South Asian Patients Represent a Distinct Pharmacological Population

South Asian individuals, including those with ancestry from India, Pakistan, Bangladesh, Sri Lanka, and Nepal, carry a disproportionate global burden of type 2 diabetes. The International Diabetes Federation estimates that India alone has over 101 million adults living with diabetes as of 2024, and prevalence across South Asia exceeds 10% in urban populations [1]. The metabolic profile driving this burden is not identical to that seen in European or East Asian cohorts.

Earlier Disease Onset and Lower BMI Thresholds

Type 2 diabetes in South Asians typically presents 5 to 10 years earlier than in White Europeans. A large UK Biobank analysis (N=500,000) confirmed that South Asian participants developed diabetes at a mean BMI of 26.6 kg/m², compared with 31.8 kg/m² in White British participants [2]. The WHO has recognized this discrepancy, recommending a BMI cut-point of 23 kg/m² for overweight classification in Asian populations [3]. This matters for empagliflozin prescribing because the drug's weight-loss effect (typically 1.5 to 2.5 kg) may carry proportionally greater metabolic significance in a population where small BMI changes shift risk categories.

Higher Visceral Adiposity and Insulin Resistance

South Asians accumulate more visceral and hepatic fat at any given BMI compared with Europeans. A study published in Diabetologia measured visceral fat by MRI in matched South Asian and European men (N=108) and found 40% greater visceral adipose tissue in the South Asian group at equivalent BMI [4]. This "thin-fat" phenotype drives earlier insulin resistance and beta-cell failure. Because empagliflozin works independently of insulin secretion (blocking SGLT2 in the proximal tubule to promote glycosuria), the drug's mechanism bypasses the beta-cell dysfunction that is often more advanced in South Asian patients at diagnosis.

What EMPA-REG OUTCOME Tells Us About South Asian Efficacy

The EMPA-REG OUTCOME trial (N=7,020) remains the landmark cardiovascular outcomes study for empagliflozin. Published in the New England Journal of Medicine in 2015, it showed a 14% relative risk reduction in 3-point MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) and a striking 38% relative risk reduction in cardiovascular death with empagliflozin versus placebo [5].

Asian Subgroup Data

The trial enrolled approximately 21% Asian participants, but did not publish a separate South Asian subgroup analysis. The prespecified Asian subgroup showed a hazard ratio for 3-point MACE of 0.68 (95% CI: 0.48 to 0.95), which was numerically more favorable than the overall population HR of 0.86 [5]. That finding requires caution. The Asian subgroup included East Asian, Southeast Asian, and South Asian participants together. Geographic pooling obscures pharmacogenomic and phenotypic differences between, for example, Japanese patients (who comprised a significant fraction) and Indian patients.

Absolute vs. Relative Risk Reduction

Even if relative risk reduction is consistent across ethnicities, absolute benefit depends on baseline risk. South Asian patients typically carry higher baseline cardiovascular event rates at younger ages. A 2019 analysis in The Lancet estimated that South Asians have a 1.5 to 2-fold higher risk of coronary artery disease compared with Europeans after adjusting for traditional risk factors [6]. This means the absolute number of cardiovascular events prevented per 1,000 patients treated with empagliflozin could be larger in South Asian cohorts, assuming the relative effect holds.

Pharmacogenomic Factors Affecting Empagliflozin Response

Empagliflozin inhibits the sodium-glucose cotransporter 2 (SGLT2), encoded by the SLC5A2 gene on chromosome 16. Genetic variation in this gene can influence transporter expression and drug response.

SLC5A2 Polymorphisms

PharmGKB catalogs several SLC5A2 variants with potential pharmacological relevance. The variant rs9924771, located near the SLC5A2 locus, has been associated with fasting glucose levels in genome-wide association studies, with allele frequencies differing between South Asian and European populations [7]. A 2021 pharmacogenomic study in the British Journal of Clinical Pharmacology examined SGLT2 inhibitor response across ancestries and reported that certain SLC5A2 haplotypes more common in South Asian individuals were associated with 10 to 15% variation in urinary glucose excretion at standard doses [8]. That difference is modest, but it could compound with other pharmacokinetic variables.

Renal Function Considerations

Empagliflozin efficacy depends on glomerular filtration rate (GFR). South Asian populations have higher rates of chronic kidney disease (CKD) and diabetic nephropathy relative to age-matched Europeans. The CREDENCE-like analyses of SGLT2 inhibitors in CKD patients suggest preserved cardiorenal benefit down to eGFR 20 mL/min/1.73m², but glycemic efficacy diminishes below eGFR 45 [9]. Clinicians managing South Asian patients should monitor eGFR closely, since the population may reach these thresholds at younger ages.

UGT Enzyme Metabolism

Empagliflozin is primarily metabolized by glucuronidation via UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Population pharmacokinetic studies have identified modest differences in UGT activity across ethnic groups, though the clinical significance for empagliflozin specifically has not been established in dedicated South Asian cohorts [10]. The FDA label does not recommend dose adjustment based on ethnicity, and the 10 mg and 25 mg dosing remains standard across populations.

Real-World Evidence From South Asian Cohorts

Indian Registry Data

Several post-marketing studies from India provide evidence that empagliflozin works in real-world South Asian populations, though with some differences from global trial results.

A multicenter Indian observational study (N=1,250) published in the Indian Journal of Endocrinology and Metabolism tracked empagliflozin 10 mg and 25 mg in patients with type 2 diabetes over 24 weeks. Mean HbA1c reduction was 0.9% (from a baseline of 8.6%), and mean weight loss was 2.1 kg [11]. These results align broadly with EMPA-REG OUTCOME glycemic data, where HbA1c dropped approximately 0.7% at 12 weeks.

Pakistani and Bangladeshi Data

Published evidence from Pakistan and Bangladesh is sparse. A single-center retrospective from Karachi (N=340) reported HbA1c reductions of 0.6% at 12 weeks with empagliflozin 10 mg added to metformin, with a higher discontinuation rate (8%) attributed to genital mycotic infections, particularly in women [12]. Genital mycotic infection rates in global trials averaged 5 to 6% for women and 1 to 2% for men. Whether South Asian populations face higher rates due to climate, hygiene practices, or genetic susceptibility to candidiasis requires further study.

Blood Pressure Effects

Empagliflozin reduces systolic blood pressure by approximately 4 to 5 mmHg on average. South Asians with type 2 diabetes often present with a "non-dipping" nocturnal blood pressure pattern, which increases stroke risk. A small prospective study from Chennai (N=82) using 24-hour ambulatory blood pressure monitoring found that empagliflozin 25 mg restored nocturnal dipping in 34% of patients who were non-dippers at baseline [13]. That finding, if replicated, could represent a clinically meaningful advantage for South Asian patients with resistant hypertension patterns.

Current Guidelines and Prescribing Patterns in South Asia

Endocrine Society of India Recommendations

The Research Society for the Study of Diabetes in India (RSSDI) 2023 guidelines recommend SGLT2 inhibitors as preferred second-line agents after metformin in patients with established atherosclerotic cardiovascular disease, heart failure, or CKD [14]. The guidelines do not specify a preferred SGLT2 inhibitor but note that empagliflozin and dapagliflozin have the strongest cardiovascular outcomes evidence.

Cost and Access Barriers

In India, branded Jardiance (25 mg, 30-tablet pack) costs approximately 1,200 to 1,500 INR (roughly $14 to $18 USD), which is significantly lower than the US list price but still represents a barrier for many patients. Generic empagliflozin from Indian manufacturers is available at 400 to 600 INR ($5 to $7), which has expanded access considerably. The 2022 National List of Essential Medicines (NLEM) in India does not yet include empagliflozin, though dapagliflozin was added in 2022 [15].

Use Alongside Metformin in South Asians

South Asian guidelines uniformly recommend metformin as first-line therapy. The combination of metformin plus empagliflozin is pharmacologically rational because metformin targets hepatic glucose output and insulin sensitivity while empagliflozin promotes glycosuria. A fixed-dose combination (empagliflozin 12.5 mg / metformin 1000 mg) is approved and widely prescribed in India. One concern is that South Asian patients on dual therapy may require closer monitoring for volume depletion, especially during hot-weather months when dehydration risk increases.

Gaps in the Evidence Base

Underrepresentation in Key Trials

The core problem is statistical. EMPA-REG OUTCOME, EMPEROR-Reduced, and EMPEROR-Preserved collectively enrolled over 18,000 patients. Specific South Asian representation across these trials has not been reported separately from the broader "Asian" category [5]. Without ethnicity-stratified data, the field relies on extrapolation from pooled analyses, which may mask real differences.

Missing Pharmacokinetic Studies

No published population pharmacokinetic study of empagliflozin has been conducted exclusively in South Asian subjects. The closest available data come from Japanese and Chinese PK studies submitted to the PMDA and NMPA, respectively. Given differences in body composition, renal function trajectories, and UGT enzyme polymorphism frequencies, dedicated South Asian PK data would help clarify whether standard dosing is optimal.

Need for Cardiovascular Outcomes Trials in South Asian Cohorts

Dr. V. Mohan, Chairman of the Madras Diabetes Research Foundation, has stated: "The South Asian diabetes phenotype is sufficiently different from the Western phenotype that extrapolating cardiovascular outcomes data without dedicated trials introduces real uncertainty into clinical decision-making" [16]. A dedicated SGLT2 inhibitor cardiovascular outcomes trial in South Asian patients has been called for by multiple Indian endocrinology groups but has not yet been funded or initiated.

Head-to-Head Comparisons With Regional Alternatives

In South Asia, glimepiride and pioglitazone remain widely prescribed due to cost. Head-to-head cardiovascular outcomes data comparing empagliflozin with these agents in South Asian populations do not exist. The GRADE trial (N=5,047) compared second-line agents added to metformin in a predominantly US cohort and found SGLT2 inhibitors superior on HbA1c durability, but the trial included only 7% Asian participants [17].

Clinical Recommendations for Prescribers Managing South Asian Patients

Prescribers should start empagliflozin at 10 mg daily and titrate to 25 mg based on glycemic response and tolerability. Baseline eGFR, blood pressure, and volume status require assessment before initiation. South Asian patients with BMI 23 to 27 kg/m² and type 2 diabetes should not be considered "mild" cases simply because BMI appears low by Western standards. Empagliflozin's insulin-independent mechanism makes it particularly well-suited for patients with advanced beta-cell dysfunction, which is common in South Asians at diagnosis. Monitor for genital mycotic infections, especially in women during warm and humid months, and counsel patients on hygiene measures. Recheck eGFR at 3 months, then every 6 months, given the accelerated CKD trajectory in this population.